These results suggest that the pharmacological blockade of sEH may be more effective in preventing the deleterious mechanisms associated with renal I/R that contribute to allograft dysfunction, especially inflammation, than those involved in the development of chronic kidney disease. The gene discussed is EPHX2; the disease is chronic kidney disease.